
Contents lists available at ScienceDirect



Gynecologic Oncology



journal homepage: www.elsevier.com/locate/ygyno

Analysis of outcomes and prognostic factors after fertility-sparing surgery in malignant ovarian germ cell tumors



Jeong-Yeol Park *, Dae-Yeon Kim, Dae-Shik Suh, Jong-Hyeok Kim, Yong-Man Kim, Young-Tak Kim, Joo-Hyun Nam

Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea

HIGHLIGHTS

- · Fertility-sparing surgery has excellent survival outcomes in early and advanced stage MOGCT.
- The pregnancy rate was 75%, and live birth rate was 65% after fertility-sparing surgery.
- · Yolk sac tumor, incomplete surgical staging, and residual tumor were independent risk factors for recurrence.
- Yolk sac tumor and residual tumor were independent risk factors for death.

ARTICLE INFO

Article history: Received 6 February 2017 Received in revised form 27 March 2017 Accepted 28 March 2017 Available online 31 March 2017

Keywords: Malignant ovarian germ cell tumor Ovary Fertility-sparing surgery Oncologic outcome Reproductive outcome

ABSTRACT

Objective. To evaluate the oncologic and reproductive outcomes and to analyze prognostic factors after fertility-sparing surgery in patients with early and advanced malignant ovarian germ cell tumors (MOGCTs).

Methods. This study included 171 patients who underwent fertility-sparing surgery. Data were gathered from patients' medical records. Survival analysis was performed using the log-rank test and Cox's proportional hazards model. Reproductive outcomes were analyzed.

Results. Twenty-five patients (14.6%) had recurrent disease, and five patients (2.9%) died of disease during the median follow-up time of 86 months (range, 9–294 months). The 5-year disease-free survival (DFS) was 86%, and the 5-year overall survival (OS) was 97%. The 5-year DFS was 84% for stage I and 89% for stage II–IV. The 5-year OS was 99% for stage I and 91% for stage II–IV. In multivariate analysis, yolk sac tumor, incomplete staging surgery, and residual tumor were independent risk factors for reduced DFS, and yolk sac tumor and residual tumor were independent risk factors for reduced OS. Reproductive and obstetric outcomes were evaluable in 124 patients, and 106 patients (85.5%) had regular menstruation, 12 patients (9.7%) had irregular menstruation, and six patients (4.8%) had premature menopause. Twenty patients tried to conceive, 15 patients (75%) succeeded in achieving 21 pregnancies, and 13 of the patients (65%) gave birth to 20 healthy babies.

Conclusion. Fertility-sparing surgery has excellent survival outcomes in young women with MOGCTs, even in advanced stages. Reproductive and obstetric outcomes were promising. Yolk sac tumor, incomplete surgical staging, and residual tumor were independent prognostic factors.

© 2017 Elsevier Inc. All rights reserved.

1. Introduction

Malignant ovarian germ cell tumor (MOGCT) is a rare ovarian malignancy, which originates from primordial germ cells. It accounts for approximately 5–7% of all ovarian malignancies [1,2]. The incidence of MOGCT has not changed over the past several decades [3,4]. Several histologic types are observed, including dysgerminoma, immature teratoma, yolk sac tumor, choriocarcinoma, polyembryoma, and mixed MOGCT [5]. The survival outcomes and cure rates are excellent

* Corresponding author. *E-mail address:* catgut1-0@hanmail.net (J.-Y. Park). because of the high chemosensitivity of MOGCTs, even in advanced stage disease [3,4].

MOGCTs usually affect children, adolescent girls, and young women who wish to preserve gonadal and reproductive function. The peak incidence is at 15–19 years of age, and MOGCTs represent approximately 70% of malignant ovarian tumors in this age group [5,6]. Therefore, fertility preservation is one of the most important quality of life issues in young patients with MOGCTs. The current treatment guideline suggests the use of fertility-sparing surgery, which is defined as the preservation of the contralateral adnexa and the uterus in early stage MOGCTs that are confined to one ovary [7]. Because of the highly chemosensitive nature of MOGCTs, fertility-sparing surgery is also performed with cytoreductive surgery in young patients with advanced MOGCTs. However, only a few studies have evaluated the oncologic and reproductive outcomes after fertility-sparing surgery in early and advanced stage MOGCTs. In addition, the prognostic factors after fertility-sparing surgery have been rarely reported. The aim of this study was to evaluate the oncologic and reproductive outcomes and to analyze the prognostic factors after fertility-sparing surgery, in patients with early and advanced MOGCTs.

2. Materials and methods

This was a retrospective study, performed in a single center after the approval of the Institutional Review Board of Asan Medical Center, Seoul, Korea. All consecutive patients with MOGCTs who underwent fertility-sparing surgery at Asan Medical Center, Seoul, Korea, between 1992 and 2015, were included in this study. Patient demographics, clinicopathologic findings, follow-up information, and reproductive outcome data were gathered from the patients' medical records. Fertility-sparing surgery was defined as the preservation of the uterus and at least one adnexa. Complete staging surgery was defined as peritoneal staging and lymph node evaluation. Peritoneal staging included peritoneal exploration, cytology, biopsy, and omentectomy or omental biopsy. Lymph node evaluation involved one of the following: 1) lymph node dissection, 2) lymph node sampling, or 3) palpation and removal of enlarged lymph nodes. Residual tumor was defined as residual MOGCTs of any size after surgery. The strategy for adjuvant chemotherapy for MOGCTs in our center is to recommend three to six cycles of bleomycin, etoposide, and cisplatin (BEP) chemotherapy in all patients, except those with stage IA dysgerminomas and stage IA grade 1 immature teratomas. All patients were evaluated at follow-up every 3 months during first 2 years after treatment, every 6 months during the next 3 years, and then once a year. The follow-up included history taking, physical examination, tumor markers, and/or imaging, including ultrasonography, magnetic resonance imaging, or computed tomography.

The association between survival outcomes and demographic and clinicopathologic factors was analyzed. Reproductive and obstetric outcomes including menstruation, premature menopause, pregnancy, and delivery were also analyzed. Disease-free survival (DFS) was calculated as the time interval, in months, between the date of surgery and the date of recurrence or censored. Overall survival (OS) was calculated as the time interval, in months, between the date of surgery and the date of death or censored. The survival curve was calculated using the Kaplan-Meier method. The difference in survival between groups was compared using the log-rank test or Cox's proportional hazards model in the univariate analysis. Multivariate survival analysis was performed using Cox's proportional hazards model, including prognostic factors that were statistically significant in the univariate analysis. Pregnancy rate was calculated by dividing the number of patients who succeeded in achieving pregnancy by the number of patients who tried to conceive. Live birth rate was calculated by dividing the number of patients who gave birth to a healthy baby by the number of patients who tried to conceive. *P*-values <0.05 in a two-sided test were regarded as statistically significant. All statistical analyses were performed using SPSS software, version 21.0 (IBM Corporation, Armonk, NY, USA).

3. Results

During the study period, 199 patients with MOGCTs underwent surgery at Asan Medical Center, and 171 of these patients who underwent fertility-sparing surgery were eligible for this study. The characteristics of the 171 patients with MOGCTs are listed in Table 1. The mean age $(\pm$ SD) of patients was 22 years (\pm 8.8 years), and 154 patients (90.1%) were nulliparous women. Immature teratoma was the most common histologic type, followed by dysgerminoma, mixed MOGCT, yolk sac tumor, choriocarcinoma, and embryonal carcinoma. A total of

Table 1	
---------	--

Characteristics of patients (n = 171).

Age, years Mean \pm SD 22 \pm 8.8 s22 years, n (%) 90 (52.6) >-22 years, n (%) 81 (47.4) Parity, n (%) Nulliparous 154 (90.1) Previous history of surgery, n (%) No 128 (74.9) Preoperative serum α -FP level ³ , n (%) Not elevated 63 (36.8) Elevated 70 (40.9) Not checked 38 (22.2) Preoperative serum β-hCG level ⁵ , n (%) Not checked 69 (40.4) Preoperative serum CA 125 level ⁶ , n (%) Not checked 27 (15.8) Elevated 13 (66.1) Not checked 31 (18.1) Histologic type, n (%) Immature tratoma 54 (31.6) Dysgerminoma 53 (31) Mixed 34 (19.9) Yolk sac tumor 25 (14.6) Choriocarcinoma 4 (2.3) Embryonal carcinoma 1 (6) 1 125 (73.1) II 125 (73.1) II 126 (73.7) FGO stage, n (%) No 79 (46.2) 14.8 ± 5.8 s15 cm 89 (52) 15 cm 82 (48) Ascites			
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	Characteristics		
$\begin{array}{ccccc} > 22 \ \text{years, } n (\%) & 81 (47.4) \\ \text{Parity, } n (\%) & \text{Nulliparous} & 154 (90.1) \\ \text{Parous} & 17 (9.9) \\ \text{Previous history of surgery, } n (\%) & \text{No} & 128 (74.9) \\ \text{Yes} & 43 (25.1) \\ \text{Preoperative serum } \alpha - \text{FP level}^*, n (\%) & \text{No televated} & 63 (36.8) \\ \text{Elevated} & 70 (40.9) \\ \text{Not checked} & 38 (22.2) \\ \text{Preoperative serum } \beta - \text{hCG level}^b, n (\%) & \text{Not checked} & 38 (22.2) \\ \text{Preoperative serum } \beta - \text{hCG level}^c, n (\%) & \text{Not checked} & 69 (40.4) \\ \text{Preoperative serum CA 125 level}^c, n (\%) & \text{Not checked} & 69 (40.4) \\ \text{Preoperative serum CA 125 level}^c, n (\%) & \text{Not checked} & 31 (18.1) \\ \text{Histologic type, } n (\%) & \text{Immature teratoma} & 54 (31.6) \\ \text{Dysgerminoma} & 53 (31) \\ \text{Mixed} & 34 (19.9) \\ \text{Yolk sac tumor} & 25 (14.6) \\ \text{Choriocarcinoma} & 4 (2.3) \\ \text{Embryonal carcinoma} & 1 (6) \\ \text{FIGO stage, } n (\%) & \text{I} & 125 (73.1) \\ \text{II} & 18 (10.5) \\ \text{II} & 125 (12.2) \\ \text{Tumor size, } n (\%) & \text{Not} & 9 (52) \\ > 15 \ \text{cm} & 89 (52) \\ > 15 \ \text{cm} & 82 (48) \\ \text{Ascites, } n (\%) & \text{Not} & 119 (69.6) \\ \text{Ves} & 9 (253.8) \\ \text{Peritoneal cytology, } n (\%) & \text{Not} & 128 (73.7) \\ \text{Positive} & 12 (7) \\ \text{Not} \ \text{Aone} & 33 (19.3) \\ \text{Tumor rupture, } n (\%) & \text{No} & 141 (82.5) \\ \text{Yes} & 30 (17.5) \\ \text{Lymph node metastasis, } n (\%) & \text{No} & 141 (82.5) \\ \text{Yes} & 10 (5.8) \\ \text{Not sampled} & 92 (53.8) \\ \text{Surgery mode, } n (\%) & \text{Open} & 151 (88.3) \\ \text{Adnexal surgery, } n (\%) & \text{LSO or UO} + \text{UOC} & 4 (2.3) \\ \text{Expansion} & 149 (69.6) \\ \text{Incomplete} & 119 (69.6) \\ \text{Incomplete} & 52 (30.4) \\ \end{array}$	Age, years	Mean \pm SD	22 ± 8.8
Parity, n (%) Nulliparous 154 (90.1) Parous Previous history of surgery, n (%) No 128 (74.9) Yes 43 (25.1) Preoperative serum α -FP level ⁸ , n (%) Not elevated 63 (36.8) Elevated 70 (40.9) Not checked 38 (22.2) Preoperative serum β -hCG level ⁶ , n (%) Not elevated 79 (46.2) Elevated 23 (13.5) Not checked 69 (40.4) Preoperative serum CA 125 level ⁶ , n (%) Not elevated 27 (15.8) Elevated 113 (66.1) Not checked 31 (18.1) Histologic type, n (%) Immature teratoma 54 (31.6) Volk sac tumor 25 (14.6) Olysgerminoma 53 (31) Mixed 34 (19.9) Yolk sac tumor 25 (14.6) FIGO stage, n (%) I 125 (73.1) II 18 (10.5) II 18 (10.5) III 26 (15.2) IV 2 (12.1) Tumor size, n (%) No 79 (46.2) 2 (32.3) 2 (32.3) Peritoneal cytology, n (%) Negative 126 (73.7) Positive		≤22 years, <i>n</i> (%)	90 (52.6)
Parous $17 (9.9)$ Previous history of surgery, n (%) No $128 (74.9)$ Yes $43 (25.1)$ Preoperative serum α -FP level ³ , n (%) Not elevated $63 (36.8)$ Elevated 70 (40.9) Not checked $38 (22.2)$ Preoperative serum β -hCG level ⁵ , n (%) Not elevated $79 (46.2)$ Preoperative serum CA 125 level ⁶ , n (%) Not checked $69 (40.4)$ Preoperative serum CA 125 level ⁶ , n (%) Not checked $13 (66.1)$ Not checked $113 (66.1)$ Not checked $31 (18.1)$ Histologic type, n (%) Immature teratoma $54 (31.6)$ Dysgerminoma $53 (31)$ Mixed $34 (19.9)$ Yolk sac tumor $25 (14.6)$ Choriocarcinoma $4 (2.3)$ FIGO stage, n (%) I $125 (73.1)$ II $18 (10.5)$ III $26 (15.2)$ N $27 (15.2)$ $27 (15.2)$ Tumor size, n (%) No $79 (46.2)$ $26 (15.2)$ IV $21 (27)$ No $79 (46.2)$ $27 (73.7)$ <tr< td=""><th></th><td>>22 years, n (%)</td><td>81 (47.4)</td></tr<>		>22 years, n (%)	81 (47.4)
Previous history of surgery, n (%) No 128 (74.9) Yes Preoperative serum α-FP level [*] , n (%) Not elevated 63 (36.8) Elevated Preoperative serum β-hCG level ^b , n (%) Not clevated 79 (46.2) Elevated 70 (40.9) Not checked 38 (22.2) Preoperative serum β-hCG level ^b , n (%) Not clevated 79 (46.2) Elevated 23 (13.5) Not checked 69 (40.4) Preoperative serum CA 125 level ^c , n (%) Not elevated 27 (15.8) Elevated 131 (66.1) Not checked 31 (18.1) Histologic type, n (%) Immature teratoma 54 (31.6) Dysgerminoma 53 (31) Mixed 34 (19.9) Yolk sac tumor 25 (14.6) Choriocarcinoma 4 (2.3) Embryonal carcinoma 1.6 Choriocarcinoma 4 (2.3) Elevated 25 (73.7) Tumor size, n (%) Mean ± SD, cm 148 ± 5.8 \$15 cm 89 (52) >15 cm 82 (48) Ascites, n (%) No 79 (46.2) Yes 20 (33.8) Peritoneal cytology, n (%)	Parity, n (%)	Nulliparous	154 (90.1)
Yes43 (25.1) Not elevatedPreoperative serum α -FP level ³ , n (%)Not elevated63 (36.8) ElevatedPreoperative serum β -hCG level ⁵ , n (%)Not elevated79 (46.2) ElevatedPreoperative serum CA 125 level ⁶ , n (%)Not elevated27 (15.8) ElevatedPreoperative serum CA 125 level ⁶ , n (%)Not elevated27 (15.8) ElevatedHistologic type, n (%)Not elevated31 (18.1) MixedHistologic type, n (%)Immature teratoma54 (31.6) ChoriocarcinomaPreoperative serum CA 125 level ⁶ , n (%)Not elevated31 (18.1) MixedHistologic type, n (%)Immature teratoma54 (31.6) Choriocarcinoma4 (2.3) 		Parous	17 (9.9)
Preoperative serum α-FP level ³ , n (%) Not elevated 63 (36.8) Elevated Preoperative serum β-hCG level ^b , n (%) Not elevated 79 (46.2) Not checked 38 (22.2) Preoperative serum CA 125 level ⁶ , n (%) Not elevated 23 (13.5) Not checked 69 (40.4) Preoperative serum CA 125 level ⁶ , n (%) Not elevated 27 (15.8) Elevated 13 (66.1) Mixed 34 (19.9) Volk sact tumor 25 (14.6) Dysgerminoma 53 (31) Mixed 34 (19.9) Yolk sact tumor 25 (14.6) Choriocarcinoma 1 (6) FIGO stage, n (%) I 125 (73.1) II 18 (10.5) II 126 (15.2) IV 26 (15.2) IV 26 (15.2) Tumor size, n (%) Mean ± SD, cm 14.8 ± 5.8 515 cm 89 (52) >15 cm 89 (52) >15 cm 82 (48) Ascites, n (%) No 19 (69.6) Yes 92 (53.8) Peritoneal cytology, n (%) No 119 (69.6) Yes 92 (53.4) Tumor rupture, n (%) No 119 (69.6) Yes 92 (53.8) </td <th>Previous history of surgery, n (%)</th> <td>No</td> <td>128 (74.9)</td>	Previous history of surgery, n (%)	No	128 (74.9)
LetterElevated70 (40.9) Not checkedPreoperative serum β-hCG level ^b , n (%)Not checked38 (22.2) Not checkedPreoperative serum CA 125 level ^c , n (%)Not checked69 (40.4)Preoperative serum CA 125 level ^c , n (%)Not checked69 (40.4)Preoperative serum CA 125 level ^c , n (%)Not checked113 (66.1)Histologic type, n (%)Immature teratoma54 (31.6)Dysgerminoma53 (31)Mixed34 (19.9)Histologic type, n (%)Immature teratoma54 (31.6)Dysgerminoma53 (31)Mixed34 (19.9)Volk sac tumor25 (14.6)Choriocarcinoma4 (2.3)Embryonal carcinoma1 (6)1125 (73.1)IIII18 (10.5)III26 (15.2)IV2 (1.2)Vels sac tumor25 (23.4)Tumor size, n (%)Mean ± SD, cm148 ± 5.8S15 cm89 (52)>15 cm82 (48)Ascites, n (%)No19 (69.6)Yes22 (30.4)Yes22 (30.4)Ovarian surface invasion, n (%)No141 (82.5)Yes30 (17.5)Yes30 (17.5)Lymph node metastasis, n (%)No141 (82.5)Surgery mode, n (%)Laparoscopy20 (11.7)Adnexal surgery, n (%)USO or UO122 (71.3)USO or UO122 (71.3)USO or UO122 (71.3)Just (Mathievel Mathievel Math		Yes	43 (25.1)
Preoperative serum β-hCG level ^b , n (%)Not checked38 (22.2) Not elevated79 (46.2) ElevatedPreoperative serum CA 125 level ^c , n (%)Not checked69 (40.4)Preoperative serum CA 125 level ^c , n (%)Not elevated27 (15.8) Elevated113 (66.1) Not checkedHistologic type, n (%)Not elevated31 (18.1)Histologic type, n (%)Immature teratoma54 (31.6) Dysgerminoma33 (31) MixedHistologic type, n (%)I125 (73.1) 	Preoperative serum α -FP level ^a , n (%)	Not elevated	63 (36.8)
Preoperative serum β-hCG level ^b , n (%) Not elevated 79 (46.2) Preoperative serum CA 125 level ^c , n (%) Not checked 69 (40.4) Preoperative serum CA 125 level ^c , n (%) Not checked 27 (15.8) Elevated 113 (66.1) Not checked 31 (18.1) Histologic type, n (%) Immature teratoma 54 (31.6) Dysgerminoma 53 (31) Mixed 34 (19.9) Yolk sac tumor 25 (14.6) Choriocarcinoma 4 (2.3) Embryonal carcinoma 1 (6) FIGO stage, n (%) I 18 (10.5) II 18 (10.5) III 18 (10.5) III 26 (15.2) IV 2 (1.2) V 2 (1.2) 2 (1.2) Tumor size, n (%) Mean ± SD, cm 82 (48) 48 ± 5.8 ≤15 cm 82 (48) 18 (57.7) Positive 12 (7.7) Ascites, n (%) No 79 (46.2) Yes 92 (53.8) Peritoneal cytology, n (%) Negative 12 (7.7) Positive 12 (7.7) Not done 33 (19.3) Not done <t< td=""><th></th><td></td><td></td></t<>			
Elevated23 (13.5) Not checkedPreoperative serum CA 125 level ^c , n (%)Not checked69 (40.4)Preoperative serum CA 125 level ^c , n (%)Not checked113 (66.1)Histologic type, n (%)Immature teratoma54 (31.6)Dysgerminoma53 (31)Mixed34 (19.9)Yolk sac tumor25 (14.6)Choriocarcinoma4 (2.3)Embryonal carcinoma1 (6)Embryonal carcinoma1 (6)FIGO stage, n (%)I18 (10.5)III26 (15.2)IU2 (1.2)V2 (1.2)Tumor size, n (%)Mean \pm SD, cm14.8 \pm 5.8 \leq 15 cm89 (52)> 15 cm82 (48)No79 (46.2)Yes92 (53.8)Peritoneal cytology, n (%)Negative126 (73.7)Positive12 (7)Not done33 (19.3)Tumor rupture, n (%)No119 (69.6)YesVarian surface invasion, n (%)No19 (69.6)Yes10 (5.8)Not sampled92 (53.8)Surgery mode, n (%)Open151 (88.3)Lymph node metastasis, n (%)USO or UO122 (71.3)USO or UO122 (71.3)Staging surgery, n (%)Gomplete119 (69.6)Incomplete52 (30.4)INO122 (71.3)			• •
Preoperative serum CA 125 level ^c , n (%)Not checked69 (40.4) Not elevated27 (15.8) ElevatedHistologic type, n (%)Immature teratoma54 (31.6) Dysgerminoma53 (31) Mixed34 (19.9) Yolk sac tumor25 (14.6) Choriocarcinoma4 (2.3) Embryonal carcinoma16)FIGO stage, n (%)I125 (73.1) II18 (10.5) III18 (10.5) III18 (10.5) IIITumor size, n (%)Kean \pm SD, cm148 \pm 5.8 \leq 15 cm89 (52) $> 15 cm89 (52)> 15 cm89 (52)> 15 cm89 (52)> 215 cm82 (48)Ascites, n (%)No79 (46.2)Yes26 (73.7)Positive12 (7.37)Positive12 (7.37)PositiveTumor rupture, n (%)No19 (69.6)Yes33 (19.3)Tumor rupture, n (%)No119 (69.6)Yes12 (7.5)Lymph node metastasis, n (%)No141 (82.5)YesSurgery mode, n (%)No141 (82.5)Yes10 (5.8)Not sampled92 (53.8)Surgery mode, n (%)No122 (71.3)USO or UO122 (71.3)USO or UOAdnexal surgery, n (%)USO or UO122 (71.3)USO or UO + UOC40 (23.4)UOC122 (71.3)USO or UO + UOC40 (23.4)UOCStaging surgery, n (%)Gomplete119 (69.6)Incomplete160,60,11$	Preoperative serum β-hCG level [®] , <i>n</i> (%)		
Preoperative serum CA 125 level ^c , n (%) Not elevated 27 (15.8) Elevated 113 (66.1) Not checked 31 (18.1) Histologic type, n (%) Immature teratoma 54 (31.6) Dysgerminoma 53 (31) Mixed 34 (19.9) Yolk sac tumor 25 (14.6) Choriocarcinoma 4 (2.3) Embryonal carcinoma 1 (6) FIGO stage, n (%) I 125 (73.1) II 18 (10.5) III II 26 (15.2) IV IV 2 (1.2) Vester terson Tumor size, n (%) Mean \pm SD, cm 41.8 \pm 5.8 s15 cm 89 (52) >15 cm 82 (48) Ascites, n (%) No 79 (46.2) Yes 92 (53.8) Peritoneal cytology, n (%) No 119 (69.6) Yes 33 (19.3) Tumor rupture, n (%) No 119 (69.6) Yes 30 (17.5) Lymph node metastasis, n (%) No 414 (82.5) Yes 30 (17.5) Lymph node metastasis, n (%) No 52 (30.4) 05.8) Sor			
Elevated113 (66.1) Not checkedHistologic type, n (%)Not checked31 (18.1) Immature teratomaHistologic type, n (%)Immature teratoma54 (31.6) DysgerminomaMixed34 (19.9) Yolk sac tumor25 (14.6) ChoriocarcinomaPGO stage, n (%)I125 (73.1) IIII126 (15.2) IV18 (10.5) IIITumor size, n (%)Mean \pm SD, cm14.8 \pm 5.8 \leq 15 cmAscites, n (%)No79 (46.2) YesPeritoneal cytology, n (%)Negative126 (73.7) PositivePositive12 (7) Not done33 (19.3) 31 (19.3)Tumor rupture, n (%)No141 (82.5) YesOvarian surface invasion, n (%)No141 (82.5) YesSurgery mode, n (%)Open151 (88.3) LaparoscopySurgery mode, n (%)Open151 (88.3) LaparoscopySurgery mode, n (%)Open119 (69.6) YesStaging surgery, n (%)Complete119 (69.6) IncompleteStaging surgery, n (%)Complete119 (69.6) Yes			
Not checked31 (18.1)Histologic type, n (%)Immature teratoma54 (31.6)Dysgerminoma53 (31)Mixed34 (19.9)Yolk sac tumor25 (14.6)Choriocarcinoma4 (2.3)Embryonal carcinoma1 (6)FIGO stage, n (%)I125 (73.1)II18 (10.5)III26 (15.2)IV2 (1.2)Tumor size, n (%)Mean \pm SD, cm44.8 \pm 5.8 ≤ 15 cm89 (52)>15 cm82 (48)Ascites, n (%)No79 (46.2)Yes92 (53.8)Peritoneal cytology, n (%)Negative126 (73.7)Tumor rupture, n (%)No119 (69.6)Yes52 (30.4)NoOvarian surface invasion, n (%)No141 (82.5)Yes10 (5.8)Not sampled92 (53.8)Surgery mode, n (%)Open151 (88.3)Laparoscopy20 (11.7)Adnexal surgery, n (%)USO or UO122 (71.3)USO or UO122 (71.3)USO or UO122 (71.3)USO or UO + UOC40 (23.4)UOC5 (2.9)BOC4 (2.3)Staging surgery, n (%)Complete19 (69.6)	Preoperative serum CA 125 level ^c , n (%)		
Histologic type, n (%)Immature teratoma Dysgerminoma54 (31.6) DysgerminomaHistologic type, n (%)Immature teratoma Dysgerminoma53 (31) MixedHistologic type, n (%)Yolk sac tumor25 (14.6) ChoriocarcinomaFIGO stage, n (%)I125 (73.1) IIII125 (73.1) II18 (10.5) IIIIII26 (15.2) IV2 (1.2)Tumor size, n (%)Mean \pm SD, cm14.8 \pm 5.8 \leq 15 cmAscites, n (%)No79 (46.2) YesPeritoneal cytology, n (%)Negative126 (73.7) PositiveTumor rupture, n (%)No119 (69.6) YesTumor rupture, n (%)No119 (69.6) YesVers30 (17.5) Lymph node metastasis, n (%)No141 (82.5) YesSurgery mode, n (%)Open151 (88.3) Laparoscopy20 (11.7) Adnexal surgery, n (%)Staging surgery, n (%)Complete122 (71.3) USO or UO122 (71.3) USO or UOStaging surgery, n (%)Complete119 (69.6) IncompleteStaging surgery, n (%)Complete119 (69.6) Incomplete			
Dysgerminoma53 (31) Mixed34 (19.9) Yolk sac tumor25 (14.6) Choriocarcinoma4 (2.3) Embryonal carcinomaFIGO stage, n (%)I125 (73.1) II125 (73.1) III18 (10.5) III18 (10.5) IIITumor size, n (%)Mean \pm SD, cm14.8 \pm 5.8 \$ 415 cmAscites, n (%)Mean \pm SD, cm14.8 \pm 5.8 \$ 90 (52) > 15 cm89 (52) > 15 cmPeritoneal cytology, n (%)No79 (46.2) YesTumor rupture, n (%)Negative12 (7) Not doneTumor rupture, n (%)No119 (69.6) YesYes52 (30.4)Ovarian surface invasion, n (%)No141 (82.5) YesLymph node metastasis, n (%)No141 (82.5) YesSurgery mode, n (%)Open151 (88.3) LaparoscopyAdnexal surgery, n (%)USO or UO122 (71.3) USO or UO + UOCMoc4 (2.3) Complete119 (69.6) IncompleteStaging surgery, n (%)Complete119 (69.6) Incomplete			. ,
Mixed34 (19.9) Yolk sac tumor25 (14.6) Choriocarcinoma4 (2.3) Embryonal carcinomaFIGO stage, n (%)I125 (73.1) I18 (10.5) IIIII18 (10.5) III26 (15.2) IV2 (1.2)Tumor size, n (%)Mean \pm SD, cm14.8 \pm 5.8 \leq 15 cm89 (52) >>15 cmAscites, n (%)No79 (46.2) Yes92 (53.8)Peritoneal cytology, n (%)Negative126 (73.7) Positive12 (7) Not doneTumor rupture, n (%)No119 (69.6) Yes33 (19.3)Tumor rupture, n (%)No119 (69.6) Yes22 (53.8)Surgery mode, n (%)No141 (82.5) Yes30 (17.5)Lymph node metastasis, n (%)No169 (40.4) Yes10 (5.8) Surgery mode, n (%)Surgery mode, n (%)Open151 (88.3) Laparoscopy20 (11.7) Adnexal surgery, n (%)Staging surgery, n (%)Complete119 (69.6) Incomplete52 (30.4)	Histologic type, n (%)		1
Yolk sac tumor25 (14.6) Choriocarcinoma4 (2.3) Embryonal carcinomaFIGO stage, n (%)I125 (73.1) IIII18 (10.5) III26 (15.2) IVTumor size, n (%)Mean \pm SD, cm14.8 \pm 5.8 \leq 15 cmAscites, n (%)No79 (46.2) YesPeritoneal cytology, n (%)Negative126 (73.7) PositiveTumor rupture, n (%)Negative126 (73.7) PositivePositive12 (7) Not done33 (19.3) 31 (19.3)Tumor rupture, n (%)No141 (82.5) YesOvarian surface invasion, n (%)No69 (40.4) YesVers30 (17.5) Lymph node metastasis, n (%)No141 (82.5) YesSurgery mode, n (%)Open151 (88.3) Laparoscopy20 (11.7) Adnexal surgery, n (%)Staging surgery, n (%)Complete119 (69.6) Incomplete119 (69.6) S (23.9)			
FIGO stage, n (%)Choriocarcinoma Embryonal carcinoma I (6)4 (2.3) Embryonal carcinoma I (6)FIGO stage, n (%)I125 (73.1)III18 (10.5)III26 (15.2)IV2 (1.2)Tumor size, n (%)Mean \pm SD, cm14.8 \pm 5.8 \leq 15 cmAscites, n (%)No79 (46.2)Yes92 (53.8)Peritoneal cytology, n (%)Negative126 (73.7) PositivePositive12 (7) Not done33 (19.3)Tumor rupture, n (%)No141 (82.5) YesOvarian surface invasion, n (%)No141 (82.5) YesSurgery mode, n (%)No141 (82.5) YesSurgery mode, n (%)Open151 (88.3) LaparoscopySurgery mode, n (%)USO or UO122 (71.3) USO or UO + UOCMoc5 (2.3) BOC4 (2.3)Staging surgery, n (%)Complete119 (69.6) Incomplete			. ,
Embryonal carcinoma1 (6)FIGO stage, n (%)I125 (73.1)III18 (10.5)III26 (15.2)V2 (1.2)Tumor size, n (%)Mean \pm SD, cm14.8 \pm 5.8 ≤ 15 cm89 (52)>15 cm82 (48)Ascites, n (%)No79 (46.2)Yes92 (53.8)Peritoneal cytology, n (%)Negative12 (7)Not done33 (19.3)Tumor rupture, n (%)No119 (69.6)Yes52 (30.4)Ovarian surface invasion, n (%)No141 (82.5)Yes30 (17.5)Lymph node metastasis, n (%)No141 (82.5)Surgery mode, n (%)Open151 (88.3)Laparoscopy20 (11.7)Adnexal surgery, n (%)USO or UO122 (71.3)USO or UO + UOC40 (23.4)UOC5 (2.9)BOC4 (2.3)Staging surgery, n (%)Complete119 (69.6)Incomplete52 (30.4)			
FIGO stage, n (%) I 125 (73.1) II 18 (10.5) III 26 (15.2) IV 2 (1.2) Tumor size, n (%) Mean \pm SD, cm 41.8 \pm 5.8 \leq 15 cm Ascites, n (%) No 79 (46.2) Yes 92 (53.8) Peritoneal cytology, n (%) Negative 126 (73.7) Positive 12 (7) Not done 33 (19.3) Tumor rupture, n (%) No 119 (69.6) Yes 30 (17.5) Lymph node metastasis, n (%) No 141 (82.5) Yes 30 (17.5) Lymph node metastasis, n (%) No 10 (5.8) Surgery mode, n (%) Open 151 (88.3) Laparoscopy 20 (11.7) 20 (11.7) Adnexal surgery, n (%) USO or UO 122 (71.3) USO or UO + UOC 40 (23.4) UOC UOC 5 (2.9) BOC 4 (2.3) Staging surgery, n (%) Complete 119 (69.6)			, ,
IIIII8 (10.5)IIII18 (10.5)III26 (15.2)IV2 (1.2)Tumor size, n (%)Mean \pm SD, cm14.8 \pm 5.8 ≤ 15 cm89 (52)>15 cm82 (48)Ascites, n (%)No79 (46.2)Yes92 (53.8)Peritoneal cytology, n (%)Negative126 (73.7)Positive12 (7)Not done33 (19.3)Tumor rupture, n (%)No119 (69.6)Yes52 (30.4)Ovarian surface invasion, n (%)No141 (82.5)Yes30 (17.5)Lymph node metastasis, n (%)No69 (40.4)Yes10 (5.8)Not sampled92 (53.8)Surgery mode, n (%)Open151 (88.3)Laparoscopy20 (11.7)Adnexal surgery, n (%)USO or UO122 (71.3)USO or UO + UOC40 (23.4)UOC5 (2.9)BOC4 (2.3)Staging surgery, n (%)Complete119 (69.6)Incomplete52 (30.4)	FICO stage = (%)	•	. ,
III $26(15.2)$ IV $2(1.2)$ Tumor size, n (%)Mean \pm SD, cm 14.8 ± 5.8 ≤ 15 cm $89(52)$ $>15 cm82(48)Ascites, n (%)No79(46.2)Yes92(53.8)Peritoneal cytology, n (%)Negative126(73.7)PositivePositive12 (7)Not done33(19.3)Tumor rupture, n (%)No141(82.5)YesOvarian surface invasion, n (%)No141(82.5)YesLymph node metastasis, n (%)No69(40.4)YesSurgery mode, n (%)Open151(88.3)LaparoscopyAdnexal surgery, n (%)USO or UO122(71.3)USO or UO + UOC40(23.4)UOC5(2.9)BOC4(2.3)Staging surgery, n (%)Complete119(69.6)Incomplete$	rigo stage, II (%)	-	, ,
IV $2 (1.2)$ Tumor size, n (%)Mean \pm SD, cm 14.8 ± 5.8 ≤ 15 cm $89 (52)$ $>15 cm82 (48)Ascites, n (%)No79 (46.2)Yes92 (53.8)Peritoneal cytology, n (%)Negative126 (73.7)PositivePositive12 (7)Not done33 (19.3)Tumor rupture, n (%)No119 (69.6)YesOvarian surface invasion, n (%)No141 (82.5)YesLymph node metastasis, n (%)No69 (40.4)YesSurgery mode, n (%)No151 (88.3)LaparoscopySurgery mode, n (%)USO or UO122 (71.3)USO or UO + UOCAdnexal surgery, n (%)Complete119 (69.6)IncompleteStaging surgery, n (%)Complete119 (69.6)Incomplete$			
Tumor size, n (%)Mean \pm SD, cm14.8 \pm 5.8 ≤ 15 cm89 (52) >>15 cmAscites, n (%)No79 (46.2) Yes92 (53.8)Peritoneal cytology, n (%)Negative126 (73.7) Positive12 (7) Not doneTumor rupture, n (%)No119 (69.6) Yes33 (19.3)Tumor rupture, n (%)No141 (82.5) Yes30 (17.5)Lymph node metastasis, n (%)No69 (40.4) Yes30 (17.5)Surgery mode, n (%)Open151 (88.3) Laparoscopy20 (11.7) Adnexal surgery, n (%)USO or UO122 (71.3) USO or UOStaging surgery, n (%)Complete119 (69.6) Incomplete52 (30.4)			
$ \begin{array}{cccc} \leq 15 \ {\rm cm} & \qquad \$9 \ (52) \\ > 15 \ {\rm cm} & \qquad \$2 \ (48) \\ \mbox{Ascites, } n \ (\%) & No & \qquad 79 \ (46.2) \\ \mbox{Yes} & \qquad 92 \ (53.8) \\ \mbox{Peritoneal cytology, } n \ (\%) & Negative & \qquad 126 \ (73.7) \\ \mbox{Positive} & 12 \ (7) \\ \mbox{Not done} & \qquad 33 \ (19.3) \\ \mbox{Tumor rupture, } n \ (\%) & No & \qquad 119 \ (69.6) \\ \mbox{Yes} & \qquad 52 \ (30.4) \\ \mbox{Ovarian surface invasion, } n \ (\%) & No & \qquad 141 \ (82.5) \\ \mbox{Yes} & \qquad 52 \ (30.4) \\ \mbox{Ovarian surface invasion, } n \ (\%) & No & \qquad 141 \ (82.5) \\ \mbox{Yes} & \qquad 30 \ (17.5) \\ \mbox{Lymph node metastasis, } n \ (\%) & No & \qquad 69 \ (40.4) \\ \mbox{Yes} & \qquad 10 \ (5.8) \\ \mbox{Not sampled} & 92 \ (53.8) \\ \mbox{Surgery mode, } n \ (\%) & \mbox{Open} & \qquad 151 \ (88.3) \\ \mbox{Laparoscopy} & 20 \ (11.7) \\ \mbox{Adnexal surgery, } n \ (\%) & \mbox{USO or UO} & 122 \ (71.3) \\ \mbox{USO or UO} + \ UOC & \qquad 40 \ (23.4) \\ \mbox{UOC} & \qquad 5 \ (2.9) \\ \mbox{BOC} & \qquad 4 \ (2.3) \\ \mbox{Staging surgery, } n \ (\%) & \mbox{Complete} & \qquad 119 \ (69.6) \\ \mbox{Incomplete} & \qquad 52 \ (30.4) \\ \end{tabular} $	Tumor size $n(\vartheta)$. ,
>15 cm82 (48)Ascites, n (%)No79 (46.2)Yes92 (53.8)Peritoneal cytology, n (%)Negative126 (73.7)Positive12 (7)Not done33 (19.3)Tumor rupture, n (%)No119 (69.6)Yes52 (30.4)Ovarian surface invasion, n (%)No141 (82.5)Yes30 (17.5)Lymph node metastasis, n (%)No69 (40.4)Surgery mode, n (%)Open151 (88.3)Laparoscopy20 (11.7)Adnexal surgery, n (%)USO or UO122 (71.3)USO or UO + UOC40 (23.4)UOC5 (2.9)BOC4 (2.3)Staging surgery, n (%)Complete119 (69.6)Incomplete52 (30.4)	1 unior size, n (%)		
Ascites, n (%) No 79 (46.2) Yes 92 (53.8) Peritoneal cytology, n (%) Negative 126 (73.7) Positive 12 (7) Positive 12 (7) Not done 33 (19.3) Tumor rupture, n (%) No 119 (69.6) Yes 52 (30.4) Ovarian surface invasion, n (%) No 141 (82.5) Yes 30 (17.5) Lymph node metastasis, n (%) No 69 (40.4) Yes 10 (5.8) Surgery mode, n (%) Open 151 (88.3) Laparoscopy 20 (11.7) Adnexal surgery, n (%) USO or UO 122 (71.3) USO or UO + UOC 40 (23.4) UOC 5 (2.9) BOC 4 (2.3) Staging surgery, n (%) Complete 119 (69.6)			
Yes 92 (53.8) Peritoneal cytology, n (%) Negative 126 (73.7) Positive 12 (7) Not done 33 (19.3) Tumor rupture, n (%) No 119 (69.6) Yes 52 (30.4) Ovarian surface invasion, n (%) No 141 (82.5) Yes 30 (17.5) Lymph node metastasis, n (%) No 69 (40.4) Yes 30 (17.5) Lymph node metastasis, n (%) No 69 (40.4) Yes 10 (5.8) Surgery mode, n (%) Open 151 (88.3) Laparoscopy 20 (11.7) Adnexal surgery, n (%) USO or UO 122 (71.3) USO or UO + UOC 40 (23.4) UOC 5 (2.9) BOC 4 (2.3) Staging surgery, n (%) Complete 119 (69.6) Incomplete 52 (30.4)	Ascites $n(\%)$. ,
$\begin{array}{cccc} \mbox{Peritoneal cytology, }n(\%) & \mbox{Negative} & 126 (73.7) \\ \mbox{Positive} & 12 (7) \\ \mbox{Not done} & 33 (19.3) \\ \mbox{Tumor rupture, }n(\%) & \mbox{No} & 119 (69.6) \\ \mbox{Yes} & 52 (30.4) \\ \mbox{Ovarian surface invasion, }n(\%) & \mbox{No} & 141 (82.5) \\ \mbox{Yes} & 30 (17.5) \\ \mbox{Lymph node metastasis, }n(\%) & \mbox{No} & 69 (40.4) \\ \mbox{Yes} & 10 (5.8) \\ \mbox{Not sampled} & 92 (53.8) \\ \mbox{Surgery mode, }n(\%) & \mbox{USO or UO} & 122 (71.3) \\ \mbox{USO or UO} + \mbox{UOC} & 40 (23.4) \\ \mbox{UOC} & 5 (2.9) \\ \mbox{BOC} & 4 (2.3) \\ \mbox{Staging surgery, }n(\%) & \mbox{Complete} & 119 (69.6) \\ \mbox{Incomplete} & 52 (30.4) \\ \end{array}$	horico, n (10)		• •
Positive 12 (7) Not done 33 (19.3) Tumor rupture, n (%) No 119 (69.6) Yes 52 (30.4) Ovarian surface invasion, n (%) No 141 (82.5) Jyph node metastasis, n (%) No 69 (40.4) Yes 10 (5.8) Surgery mode, n (%) Open 151 (88.3) Laparoscopy 20 (11.7) Adnexal surgery, n (%) USO or UO 122 (71.3) USO or UO + UOC 40 (23.4) UOC 5 (2.9) BOC 4 (2.3) Staging surgery, n (%) Complete 119 (69.6) Incomplete 52 (30.4)	Peritoneal cytology, $n(\%)$		
$\begin{array}{cccc} & \text{Not done} & 33 (19.3) \\ \text{Tumor rupture, }n (\%) & \text{No} & 119 (69.6) \\ \text{Yes} & 52 (30.4) \\ \text{Ovarian surface invasion, }n (\%) & \text{No} & 141 (82.5) \\ \text{Yes} & 30 (17.5) \\ \text{Lymph node metastasis, }n (\%) & \text{No} & 69 (40.4) \\ \text{Yes} & 10 (5.8) \\ \text{Not sampled} & 92 (53.8) \\ \text{Surgery mode, }n (\%) & \text{Open} & 151 (88.3) \\ \text{Laparoscopy} & 20 (11.7) \\ \text{Adnexal surgery, }n (\%) & \text{USO or UO} & 122 (71.3) \\ \text{USO or UO} + \text{UOC} & 40 (23.4) \\ \text{UOC} & 5 (2.9) \\ \text{BOC} & 4 (2.3) \\ \text{Staging surgery, }n (\%) & \text{Complete} & 119 (69.6) \\ \text{Incomplete} & 52 (30.4) \\ \end{array}$		•	, ,
$\begin{array}{cccc} \mbox{Tumor rupture, }n(\%) & No & 119 (69.6) \\ \mbox{Yes} & 52 (30.4) \\ \mbox{Ovarian surface invasion, }n(\%) & No & 141 (82.5) \\ \mbox{Yes} & 30 (17.5) \\ \mbox{Lymph node metastasis, }n(\%) & No & 69 (40.4) \\ \mbox{Yes} & 10 (5.8) \\ \mbox{Not sampled} & 92 (53.8) \\ \mbox{Surgery mode, }n(\%) & Open & 151 (88.3) \\ \mbox{Laparoscopy} & 20 (11.7) \\ \mbox{Adnexal surgery, }n(\%) & USO or UO & 122 (71.3) \\ \mbox{USO or UO + UOC} & 40 (23.4) \\ \mbox{UOC} & 5 (2.9) \\ \mbox{BOC} & 4 (2.3) \\ \mbox{Staging surgery, }n(\%) & Complete & 119 (69.6) \\ \mbox{Incomplete} & 52 (30.4) \\ \end{array}$			
Yes52 (30.4)Ovarian surface invasion, n (%)No141 (82.5)Yes30 (17.5)Yes30 (17.5)Lymph node metastasis, n (%)No69 (40.4)Yes10 (5.8)Not sampled92 (53.8)Surgery mode, n (%)Open151 (88.3)Laparoscopy20 (11.7)Adnexal surgery, n (%)USO or UO122 (71.3)USO or UO + UOC40 (23.4)UOC5 (2.9)BOC4 (2.3)Staging surgery, n (%)Complete119 (69.6)Incomplete52 (30.4)	Tumor rupture, n (%)	No	
$\begin{array}{cccc} \text{Ovarian surface invasion, }n(\%) & \text{No} & 141 (82.5) \\ & \text{Yes} & 30 (17.5) \\ \text{Lymph node metastasis, }n(\%) & \text{No} & 69 (40.4) \\ & \text{Yes} & 10 (5.8) \\ & \text{Not sampled} & 92 (53.8) \\ & \text{Surgery mode, }n(\%) & \text{Open} & 151 (88.3) \\ & \text{Laparoscopy} & 20 (11.7) \\ \text{Adnexal surgery, }n(\%) & \text{USO or UO} & 122 (71.3) \\ & \text{USO or UO} + \text{UOC} & 40 (23.4) \\ & \text{UOC} & 5 (2.9) \\ & \text{BOC} & 4 (2.3) \\ \\ \text{Staging surgery, }n(\%) & \text{Complete} & 119 (69.6) \\ & \text{Incomplete} & 52 (30.4) \\ \end{array}$			
Lymph node metastasis, n (%) No 69 (40.4) Yes 10 (5.8) Surgery mode, n (%) Open 151 (88.3) Laparoscopy 20 (11.7) Adnexal surgery, n (%) USO or UO 122 (71.3) USO or UO + UOC 40 (23.4) UOC 5 (2.9) BOC 4 (2.3) Staging surgery, n (%) Complete 119 (69.6)	Ovarian surface invasion, n (%)	No	
Yes 10 (5.8) Not sampled 92 (53.8) Surgery mode, n (%) Open 151 (88.3) Laparoscopy 20 (11.7) Adnexal surgery, n (%) USO or UO 122 (71.3) USO or UO + UOC 40 (23.4) UOC 5 (2.9) BOC 4 (2.3) Staging surgery, n (%) Complete 119 (69.6) Incomplete 52 (30.4)		Yes	30 (17.5)
$\begin{array}{cccc} & \text{Not sampled} & 92 (53.8) \\ \text{Surgery mode, }n (\%) & \text{Open} & 151 (88.3) \\ \text{Laparoscopy} & 20 (11.7) \\ \text{Adnexal surgery, }n (\%) & \text{USO or UO} & 122 (71.3) \\ \text{USO or UO} + \text{UOC} & 40 (23.4) \\ \text{UOC} & 5 (2.9) \\ \text{BOC} & 4 (2.3) \\ \text{Staging surgery, }n (\%) & \text{Complete} & 119 (69.6) \\ \text{Incomplete} & 52 (30.4) \end{array}$	Lymph node metastasis, n (%)	No	69 (40.4)
Surgery mode, n (%) Open 151 (88.3) Laparoscopy 20 (11.7) Adnexal surgery, n (%) US0 or UO 122 (71.3) US0 or UO + UOC 40 (23.4) UOC 5 (2.9) BOC 4 (2.3) Staging surgery, n (%) Complete 119 (69.6) Incomplete 52 (30.4)		Yes	10 (5.8)
Laparoscopy 20 (11.7) Adnexal surgery, n (%) USO or UO 122 (71.3) USO or UO + UOC 40 (23.4) UOC 5 (2.9) BOC 4 (2.3) Complete 119 (69.6) Incomplete 52 (30.4) 110 (50.6)		Not sampled	92 (53.8)
Adnexal surgery, n (%) USO or UO 122 (71.3) USO or UO + UOC 40 (23.4) UOC 5 (2.9) BOC 4 (2.3) Staging surgery, n (%) Complete 119 (69.6) Incomplete 52 (30.4)	Surgery mode, n (%)	Open	151 (88.3)
USO or UO + UOC 40 (23.4) UOC 5 (2.9) BOC 4 (2.3) Staging surgery, n (%) Complete 119 (69.6) Incomplete 52 (30.4)		Laparoscopy	20 (11.7)
UOC 5 (2.9) BOC 4 (2.3) Staging surgery, n (%) Complete 119 (69.6) Incomplete 52 (30.4)	Adnexal surgery, n (%)		122 (71.3)
BOC 4 (2.3) Staging surgery, n (%) Complete 119 (69.6) Incomplete 52 (30.4)			. ,
Staging surgery, n (%) Complete 119 (69.6) Incomplete 52 (30.4)			
Incomplete 52 (30.4)			
	Staging surgery, n (%)		, ,
	Residual tumor, n (%)	No	166 (97.1)
Yes 5 (2.9)		Yes	5 (2.9)

CA 125, cancer antigen 125; α -FP, alpha-fetoprotein; β -hCG, beta-human chorionic gonadotropin; FIGO, the International Federation of Obstetrics and Gynecology; USO, unilateral salpingo-oophorectomy; UO, unilateral oophorectomy; UOC, unilateral ovarian cystectomy; BOC, bilateral ovarian cystectomy.

Reference range: 0-20 ng/mL.

Reference range: 0-3 mIU/mL.

^c Reference range: 0–35 U/mL.

125 patients (73.1%) had International Federation of Obstetrics and Gynecology (FIGO) stage I disease. None of the patients received neoadjuvant chemotherapy. The surgery mode was open surgery in 151 patients (88.3%), and the type of adnexal surgery performed was a unilateral salpingo-oophorectomy or an oophorectomy in 162 patients (94.7%). Complete staging surgery was performed in 119 patients (69.6%), and residual tumor was present in five patients (2.9%). Of five patients with residual tumor, two patients had stage IIIC dysgerminoma and each one patient had stage IIIC yolk sac tumor, stage IIIC embryonal carcinoma, and stage IV mixed MOGCT (yolk sac tumor and immature teratoma). Ascites was present in 92 patients (53.8%), and tumor rupture was reported in 52 patients (30.4%). The pathology report revealed positive peritoneal cytology in 12 patients (7%), ovarian surface

Download English Version:

https://daneshyari.com/en/article/5695761

Download Persian Version:

https://daneshyari.com/article/5695761

Daneshyari.com